Marc Voigt - Executive Director & CEO - Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for ...19 hours ago — Immutep's CEO, stated, "Our late-stage and registrational trial programs continue to progress well, and we are pleased to see positive clinical ...4 days ago — A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Pointerra (ASX:3DP) and Zeus Resources (ASX:ZEU).People also ask
Media, page-470
-
- There are more pages in this discussion • 274 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2506 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 8079 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |